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Abstract
Background: Network pharmacology has emerged as a new topic of study in recent years. It aims to study the
myriad relationships among proteins, drugs, and disease phenotypes. The concept of molecular connectivity maps
has been proposed to establish comprehensive knowledge links between molecules of interest in a given
biological context. Molecular connectivity maps between drugs and genes/proteins in specific disease contexts can
be particularly valuable, since the functional approach with these maps helps researchers gain global perspectives
on both the therapeutic profiles and toxicological profiles of candidate drugs.
Methods: To assess drug pharmacological effect, we assume that “ideal” drugs for a patient can treat or prevent
the disease by modulating gene expression profiles of this patient to the similar level with those in healthy people.
Starting from this hypothesis, we build comprehensive disease-gene-drug connectivity relationships with drug-
protein directionality (inhibit/activate) information based on a computational connectivity maps (C2Maps) platform.
An interactive interface for directionality annotation of drug-protein pairs with literature evidences from PubMed
has been added to the new version of C2Maps. We also upload the curated directionality information of drug-
protein pairs specific for three complex diseases - breast cancer, colorectal cancer and Alzheimer disease.
Results: For relevant drug-protein pairs with directionality information, we use breast cancer as a case study to
demonstrate the functionality of disease-specific searching. Based on the results obtained from searching, we
perform pharmacological effect evaluation for two important breast cancer drugs on treating patients diagnosed
with different breast cancer subtypes. The evaluation is performed on a well-studied breast cancer gene expression
microarray dataset to portray how useful the updated C2Maps is in assessing drug efficacy and toxicity information.
Conclusions: The C2Maps platform is an online bioinformatics resource that provides biologists with directional
relationships between drugs and genes/proteins in specific disease contexts based on network mining, literature
mining, and drug effect annotating. A new insight to assess overall drug efficacy and toxicity can be provided by
using the C2Maps platform to identify disease relevant proteins and drugs. The case study on breast cancer
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Background
Screening millions of chemical compounds to identify
“hit” compounds for specific disease gene/protein targets
has been a mainstream paradigm for modern drug discov-
ery [1]. While the conventional “One disease, One gene,
and One drug” paradigm [2] works effectively for simple
genetic disorders, it fails to produce effective drugs for
complex diseases such as cancer [3]. In complex diseases,
many genes may be contributing to the disease’s pheno-
type; therefore, identifying a “magic bullet” drug com-
pound can be quite elusive.
Polypharmacology, which focuses on multi-target drugs,
has become a new paradigm in drug discovery. Polyphar-
macology drugs have conventionally been viewed to have
undesirable ‘promiscuity’. However, recent research stu-
dies show, in the case of both older psychiatric drugs and
modern anticancer therapies, that this promiscuity is
intrinsic to the drug’s therapeutic efficacy [4]. Although
there are over 40 drug-target (protein-compound interac-
tion) databases according to Pathguide [5], (e.g. DrugBank
[6], STITCH [7], CTT [8], CTD [9] and BindingDB [10],
et al), a disease-specific searching platform is still needed
to fully understand drug effects on the human body.
A new cancer systems biology approach to drug discov-
ery has emerged in recent years. The primary focus of this
paradigm is to understand the actions of drugs by consid-
ering targets in the context of the biological networks. By
focusing on a systems level, it provides a better way to
examine complicated diseases that can be caused by sev-
eral gene mutations, such as cancer [11]. However, most
methods published so far focus on modeling the structure
of the drug target network qualitatively [12]. To examine a
drug’s effect on a molecular network representative of the
disease, more quantitative and accurate modeling techni-
ques need to be developed by utilizing the concept of net-
work pharmacology [11] or network medicine [13].
In post-genome biology, molecular connectivity maps
have been proposed to establish comprehensive knowledge
links between molecules of interest in a given biological
context [14]. Molecular connectivity maps between drugs
and genes/proteins in a disease-specific context can be
particularly valuable because they allow researchers to
evaluate drugs against each other using their unique gene/
protein-drug association profiles. The functional approach
to drug comparisons helps researchers gain global per-
spectives on both the toxicological profiles and therapeutic
profiles of candidate drugs. Furthermore, the time it takes
to develop high quality drugs in new therapeutic areas can
also be reduced by using this method.
One approach for developing molecular connectivity
map data is to generate disease-specific protein-drug
association profiles computationally by mining bio mole-
cular interaction networks and PubMed literature [15].
The Connectivity Maps (C2Maps) web server [16] is an
online bioinformatics resource that provides biologists
with potential relationships between drugs and genes/
proteins in specific disease contexts based on network
mining and literature mining. It’s based on the concept
of network pharmacology by examining many drugs at
the same time and studying the drug disease relation-
ship based on the underlying protein interaction net-
work instead of drugs’ direct target. C2Maps provides
quantitative measurements of protein’s and drug’s rele-
vance to a specific disease by applying networking
mining and the statistical testing methods in text mining
and thus offers new insight to assess overall drug effi-
cacy and toxicity.
Occurrences between proteins and drugs from litera-
ture mining of C2Maps don’t necessarily tell research
what type of relationships they have, therapeutic or toxic.
To overcome these limitations, we further standardize
the classifications between proteins and drugs and then
perform literature curations to determine drugs’ effect on
proteins on higher resolutions. Such valuable information
is not readily available from the existing drug-target (pro-
tein-compound interaction) databases (e.g. DrugBank,
STITCH, CTT, et al) though they may be scattered
within a description or referenced text.
To assess drug pharmacological effect, such as drug
efficacy and toxicity, we assume that “ideal” drugs for a
patient diagnosed with a certain disease should modulate
the gene expression profiles of this patient to the similar
level with those in normal healthy people. Therefore, for
those statistically over-expressed genes, drugs should be
able to inhibit their expression level to the normal range.
Similarly, for those statistically under-expressed genes,
drugs should be able to activate their expression level to
the normal range. In this way, drugs can treat or prevent
the disease through reversing the gene expression level
from disease status to the normal range, thus modulating
cellular function as in normal cells.
By assuming that if the gene expression profiles of
disease and drug are opposing, then the drug might be
a potential treatment option of the disease, [14] identi-
fied novel drug indications in diet-induced obesity or
Alzheimer’s disease. Another work by Atul [17] utilized
the same gene expression data and algorithms with
large scale gene expression data from GEO to study
associations between 100 diseases and 164 drug mole-
cules. They found candidate therapeutics for 53 of the
diseases. These studies are proof of principle that how
using public genomics database and similar hypothesis
can benefit drug discovery. Though gene expression
data are publicly available for more than 1000 com-
pounds in the second release of [14], yet there are
numerous compounds that are not part of the data-
base. Another limitation of this overly simplified
hypothesis lies in it doesn’t differentiate important
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genes from unimportant ones. Ideally a biological
meaningful scoring methods needs developed.
Drugs effect data from literatures could be comple-
mentary here. In this work, we focus on building com-
prehensive disease-gene-drug connectivity relationships
with drug-protein directionality (inhibit/activate) infor-
mation based on the C2Maps platform [16]. To show
the feasibility of applying the data for computational
drug discovery, we advanced previous hypothesis for-
ward by assigning different weights to different genes.
However this work aims to provide the data for the
future network pharmacology research instead of devel-
oping a drug efficacy prediction method .This work has
the following contributions:
1) It’s the first time that we have published this compre-
hensive C2Maps database server. Although [16] provides
the underlying computational methodology, it only covers
a small number of diseases such as Alzheimer’s Disease.
2) We create an interactive interface for directionality
annotation of drug-protein pairs with literature evi-
dences from PubMed.
3) We curate the directionality information of drug
protein pairs for three disease phenotypes: breast cancer,
colorectal cancer and Alzheimer disease from 5133,
4869 and 3928 PubMed abstracts, respectively. We also
upload these curated directionality information into the
C2Maps, and perform a statistical analysis on them.
Curation of additional diseases, like pancreatic cancer
and autism, is still on-going.
4) We enhance the functionality of disease-specific
searching for relevant proteins and drugs with direction-
ality information.
5) We update the comprehensive disease-gene-drug
connectivity data in the C2Maps databases, including
19,569,563 PubMed abstracts in the current version and
142,523 unique 3 star protein interactions in the current
version.
6) We also use breast cancer as a case study to
demonstrate the functionality of disease-specific search-
ing for relevant drug-protein pairs with directionality
information.
7) Based on the searching result, we show the feasibility
of performing drug pharmacological effect evaluation for
two important breast cancer drugs to show the power of
updated C2Maps in drug efficacy and toxicity assessment.
Materials and methods
Data sources and systems design
As shown in Figure 1, the C2Maps platform incorpo-
rates three major components in its systems design:
• Network mining component takes a query disease
term as the input, and generates a ranked list of dis-
ease-relevant proteins as the output, through 1)
MeSH term matching, 2) disease-associated gene
searching from OMIM [18], 3) network expanding
in HAPPI [19], and 4) network-based protein
ranking;
• Text mining component takes an input list of genes
or proteins, and creates a list of enriched disease can-
didate drugs that are significantly associated with the
disease-relevant proteins from the previous compo-
nent as the output, through 1) gene/protein name
mapping using UniProtKB, 2) article abstract retrieving
from PubMed, 3) drug/chemical compound identifica-
tion using MeSH term, and 4) disease-specific drug-
protein pair ranking;
• Drug effect annotating component can allow users to
1) retrieve disease-specific drug-protein association
list, 2) curate drug-protein directionality information
from PubMed abstract, 3) annotate these drug-protein
directionality information interactively, and 4) browse
disease-specific drug-protein directionality information
online.
In specific, we apply the network mining method origin-
ally developed by Chen et al. [20] to fish cancer relevant
proteins from the protein interaction network. We expand
cancer related genes/proteins using PPIs recorded in the
Human Annotated and Predicted Protein Interactions
(HAPPI) database to construct cancer-specific PPI sub-
network. A protein’s cancer relevance score rp is calculated
as the function (1).
rp = k ln(
∑
q∈NETconf (p, g)) − ln(
∑
q∈NETN(p, q)) (1)
Here, p and q are indices for proteins in the cancer-
related interaction network PPI, k is an empirical con-
stant (k=2 in this study), conf(p, q) is the confidence
score assigned to each interaction between protein p
and q, and N(p, q) holds the value of 1 if the protein p
interacts with q.
To retrieve the important drugs for cancers and to
parse out drug terms in the articles, we acquire PubMed
abstracts with the list of cancer-related genes/proteins
derived earlier from PPI as queries. Drug term fre-
quency is calculated and compared to term statistical
distributions from the entire PubMed abstracts to get
the p-value of drugs using function (2).
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refers to a random sample generated by randomly
sampling the entire number of PubMed abstracts; the
size of the random sample is NRandom . df (dj|T ′NET) and
df (dj|T ′Random) refer to average document frequencies







Var(dj|T ′Random) refer to document frequency variances
of dj in T
′
NET and in T
′
Random . A two-sided tails t-test
was then performed to calculate the p-value. A thor-
ough description of the computational components
Figure 1 CMap workflow for a given disease-specific study.
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and algorithms used, along with data sets and data
processing parameters, is described in detail by Li
et al. [16].
The C2Maps platform follows a multi-tier architecture
design. The back end was implemented as PL/SQL
packages in the Oracle 11 g database server, with the
Oracle Text engine enabled, to ensure scalable querying
of PubMed text documents. The C2Maps application
middleware was implemented in the Oracle Application
Express (APEX) server, which bridged between the
Apache web server and the Oracle database server.
The current release of C2Maps uses the following data
sets: 19,569,563 records in the PubMed/MEDLINE base-
line database [21], 142,523 human protein-protein inter-
actions above 3-star confidence ratings in the HAPPI
database [19], 26,142 descriptors in the MeSH database
(Category C for diseases and Category D for chemicals
and drugs) [22], 20,331 entries for the curated human
proteins in the UniProtKB database [23], 18,344 entities
in the OMIM database [24], and 4,772 entities in the
DrugBank. Current statistics for the included database
records is also shown in Table 1. We manually curated
the top 500 drug-protein pairs for ‘Alzheimer disease’,
‘Breast cancer’ and ‘Colorectal cancer’ from C2Maps by
assigning the effects of drugs on proteins as defined in
the next section. As a result, C2Maps platform contains
3928, 5133 and 4869 curated records for Alzheimer dis-
ease, Breast cancer and colorectal cancer, respectively.
All data is warehoused in a local Oracle 11 g database.
Drug effect annotation
Since our hypothesis is that ideal drugs for a patient diag-
nosed with a certain disease should modulate the gene
expression profile of this patient to the similar level with
those in healthy people, we annotate a drug’s pharmaco-
logical effect on a protein using one of the following
three categories (also illustrated in Figure 2):
• Therapeutic: if the drug activates the under-
expressed protein or inhibits the over-expressed pro-
tein, we define that the drug has a therapeutic effect
on that protein
• Toxic: if the drug activates the over-expressed pro-
tein or inhibits the under-expressed protein, we
define that the drug has a toxic effect on that
protein
• Ambiguous: if there is missing directionality infor-
mation for either the nodes (i.e. proteins/drugs) or
edges.
Perturbation effects of drugs on proteins/genes
We use breast cancer as an example to illustrate how we
curate the directionality of a drug-protein pair retrieved
from the C2Maps platform. The following are four cate-
gories of an annotated drug-protein relationship pair
(also, refer to Table 2):
• Activation - “Subsequent injection of tamoxifen
triggers the transient activation of Akt/PKB in mice.”
(Tamoxifen and AKT1_HUMAN, PMID: 12640620).
• Inhibition - “Treatment of cells with Cycloheximide
(CHX) prevented the activation of p53 in all phases of
the cell cycle and its accumulation in G1/S and S.”
(P53_HUMAN and Cycloheximide, PMID:9484835).
• Indirect Yes - “Hydroxyurea-mediated DNA synth-
esis arrest of S phase MCF7 cells led to a loss of
BRCA1 from these structures.” (BRCA1_HUMAN
and Hydroxyurea, PMID:9267023).
• Ambiguous - “GRalpha and GRbeta transcripts are
coordinately upregulated in CEM-C7 cells and
coordinately downregulated in IM-9 cells by dexa-
methasone.” (GCR_HUMAN and Dexamtheasone,
PMID:12974663).
We can see that the literature does contain such infor-
mation and thus provides basis for the directionality infor-
mation retrieval. We focus on curating drug actions in the
disease context rather than only in cell lines like in [14].
Different research works under specific contexts may pro-
duce conflicting conclusions regarding drug protein rela-
tionship. Take Tamoxifen and estrogen receptor as
examples. As shown in Table 3, we successfully extracted
7 article abstracts which support the inhibitory effects of
Tamoxifen on estrogen receptor and 2 PubMed abstracts
which support the stimulatory effects of Tamoxifen on
estrogen receptor. The pre-dominant evidence showing
Tamoxifen’s inhibition on estrogen receptor [25] matches
Table 1 Current statistics for the included database records
Dataset Data Resource Record count
Biomedical Literature PubMed 19,569,563
Human Protein-Protein Interaction Unique HAPPI 3-star interactions 142,523
Disease and Drug Terminology MeSH descriptors 26,142
Human Protein UniProtKB 20,331
Disease-Gene relationships OMIM 18,344
Drug Information DrugBank 4,772
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well with the fact that Tamoxifen acts as an antagonist for
estrogen receptor. Beside checking the majority vote of all
the related papers, we also traced back the original refer-
ences. For Tamoxifen, it inhibits estrogen receptor in the
mammary tissue while activating estrogen receptor in
bone density. In our breast cancer case study, we decided
Tamoxifen inhibits estrogen receptor because the gene
expression experiment was based on breast tissue. In the
future, we plan to add additional contexts such as experi-
mental conditions, disease subtypes and so on. In the cur-
rent version, they are not added due to limited availability
of those data in abstracts.
Data access and website usage
The C2Maps online platform (http://bio.informatics.iupui.
edu/cmaps) provides researchers a web-based bioinfor-
matics user interface, following principles described in
[26]. As shown in Figure 3, users can begin with a single
disease term as a query and navigate to extract significant
subsets of the disease-specific C2Maps. We also show
snapshots of C2Maps output web pages in Figure 4, using
“Breast Cancer” as a query example. The statistically sig-
nificant relationships between proteins and drugs that are
extracted from the literature are then displayed in tabular
format (Figure 4). The proteins, drugs, and evidence
numbers are further linked to protein, drug, and the
article detail page, respectively. The search results can
also be sorted by the protein ranking score (R-Score) and
Chemical/Drug significance (P-Value). In addition, the
page also lists Disease Context (disease name of user
interest) and Disease Terminology (disease name contain-
ing query term in the controlled vocabulary of Medical
Subject Headings). Users can also specify advanced search
criteria for further biological/pharmacological analysis.
Annotations for the extracted relations could be per-
formed from the ‘Annotate Data’ tab.
Browsing disease-specific drug-protein relationship
information
Any public C2Maps database user can access the well
curated drug-protein directionality data. The database will
display disease, protein, drug directionality, and PudMed
evidence for each record. Each column can be sorted or
filtered. One can also display only drug-protein direction-
ality belonging to certain disease by selecting it from the
drop down list (Figure 5b). Furthermore, the user can also
search the keywords, such as protein name or drug name,
to retrieve only specific records. Currently, the C2Maps
platform contains 3928 curated records for Alzheimer dis-
ease, 5133 curated records for breast cancer, and 4869
curated records for colorectal cancer. More curation infor-
mation will be updated regularly.
Figure 2 Illustration of drug pharmacological effects based on directionality information for drug-protein pairs.
Table 2 Curation of drug-protein relations from Pub-Med abstracts
Relation Protein Drug PMID Relation Proof
Up-Regulated BRCA1 Estradiol 7553629 “BRCA1 mRNA and protein levels were significantly decreased in estrogen-depleted
MCF-7 and BT20T cells and increased again after stimulation with beta-estradiol”.
Down-Regulated P53 Cycloheximide 9484835 “Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all
phases of the cell cycle and its accumulation in G1/S and S”.
Indirect BRCA1 Hydroxyurea 9267023 “Hydroxyurea-mediated DNA synthesis arrest of S phase MCF7 cells led to a loss of
BRCA1 from these structures”.
Ambiguous GCR Dexamethasone 12974633 “GRalpha and GRbeta transcripts are coordinately upregulatedin CEM-C7 cells and
coordinately downregulated in IM-9 cells by dexamethasone”.
Unknown AKT1 Phosphothreonine 11087733 The drug-protein relation is not mentioned in the text.
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Interactive interface for directionality annotation
An authorized C2Maps database user can also annotate
selected C2Maps contents by performing manual curation
from the ‘Annotate Data’ tab. The user may apply for an
annotator’s account to edit protein-drug interactions sug-
gested by the C2Maps automated recommendation system.
This editing is provided through a separate user interface
that enables the annotator to categorize protein-drug
relationships as direct (including activation, inhibitory,
ambiguous), indirect, or unknown (Figure 6f). The user
will first select the assigned disease and the C2Maps web-
server will populate disease relevant protein and drug
pairs. All the PudMed abstracts mentioning both the rele-
vant protein and drug will be pulled out and the curator
can read the abstract to annotate the directionality
between the drug and the protein. The user can also edit
(Figure 6d) each record or delete it.
Results
Statistical analysis for reliability
The major computational components of the C2Maps
platform were developed using validated computational
techniques. In the network mining component, protein
interaction network expansion was able to reduce the
initial biases and low data coverage, which may have
existed in the seed list of protein. We used the new
HAPPI database instead of other protein interaction data-
bases because of its overall better data quality (comparable
or better than data in the HPRD database for quality star
grades of 3 and above) and coverage (more than 280,000
human protein interactions with star grades of 3 and
Table 3 PubMed evidence for Tamoxifen’s effect on ESR1
Drug Protein PMID Direction
Tamoxifen ESR1_HUMAN 14507640 -1
Tamoxifen ESR1_HUMAN 2359140 -1
Tamoxifen ESR1_HUMAN 14759988 -1
Tamoxifen ESR1_HUMAN 11774281 -1
Tamoxifen ESR1_HUMAN 2137212 -1
Tamoxifen ESR1_HUMAN 9328205 -1
Tamoxifen ESR1_HUMAN 11261829 -1
Tamoxifen ESR1_HUMAN 12767276 1
Tamoxifen ESR1_HUMAN 11812086 1
1 represents that the drug up regulates the protein while -1 represents down
regulation
Figure 3 The navigational site map of the CMap platform. The numbers refer to: 0. Configure search preference; 1. Input interest disease; 2.
Generate Protein-Drug connectivity; 3. Refine initially constructed connectivity map; 4. Link to protein page; 5. Link to drug page; 6. Link
between protein and drug pages; 7. Link to evidence article pages; 8. Link to external data resources (MeSH, UniProt and PubMed); 9. Import
enriched disease specific protein-drug associations for further annotation; 10; Authorized users (curators) set up profiles and login in; 11.
Annotate effects of drugs on protein/genes; 12. Release annotation results; 13. Browse annotated disease-protein-drug connectivity relationships;
14. Filter or search for interested subset of connectivity relationships.
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above), which was thoroughly described in Chen et al.
[19]. In the text mining component, the PubMed abstract
retrieval for each protein was shown to improve Informa-
tion Retrieval (IR) recall performance without sacrificing
precision The quality of disease drug identifications was
shown to outperform comparable systems with balanced
sensitivity, specificity, and positive predictive values (for
details, refer to Li et al. [16]).
In Table 4, we show a summary of C2Maps platform
performance, by comparing its overall sensitivity,
specificity, PPV (positive predictive value), F-score, and
ACC (accuracy) measures among a number of cancers.
The result confirmed that C2Maps performed well con-
sistently across different disease studies.
A case study on breast cancer specific searching for
relevant drug-protein pairs with directionality information
We evaluated breast cancer drugs from C2Maps based
on our hypothesis. First, we obtained top 500 drug pro-
tein pairs for breast cancer from the C2Maps web server,
Figure 4 Web Interface for C2Maps basic query function. (a) C2Maps default home page with a query box; (b) Preference configuration page
with editable parameters in network mining component and text mining component; (c) Disease-specific protein-drug connectivity map page
shows disease-relevant proteins, their ranking score, and drugs, their p-value, their relative frequency, as well as evidences supporting the
protein-drug associations; (d) Filter result page shows the subset of the connectivity map; (e) Protein detail page shows the disease-related
protein, its partner proteins in interaction network, and related drugs in retrieved abstracts; (f) Drug detail page shows the disease-related drugs,
its neighbor drugs in Medical Subject Heading Tree, and related proteins in disease-specific protein interaction network; (g) Article detail page
shows the literature references in PubMed with protein entity and drug entity highlighted.
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23 drugs and 103 proteins, respectively. The rp scores
for those proteins range from 1.69 to 169.82 and the P-
Values for those drugs are all below 0.05. Well known
breast cancer related proteins, like BRCA1, or related
drugs, like tamoxifen, were included in these 500 pairs.
We then examined all supporting evidence for each
drug protein relations, a total of 5,225 PubMed
abstracts, and manually curated them to extract the rele-
vant drug effect information. Out of those 500 pairs, 155
pairs contained information of how the drug affects the
protein in the literature, yielding a total of 19 drugs and
52 proteins. After performing manual curation, 79 drug
protein pairs contained only up-regulation information,
57 only down-regulation information, 11 primarily up-
regulation information, and 8 primarily down-regulation
information. The distribution of directionality categories
for breast cancer is shown in Figure 7a.A subnetwork
based on the directionality information specific for
Tamoxifen can be constructed from C2Maps directional-
ity data (shown in Figure 7b). Another subnetwork
based on the directionality information specific for Pli-
camycin is also shown in Figure 7e.
Figure 5 Web Interface for CMap Annotation data browse. (a) Annotation Data: main search page allowing either public browse or
authorized curation; (b) Annotation Data Browse: displaying curated directionality between drug and proteins for certain disease; (c) Filtering:
Each column support filtering (e.g., only show ‘Down regulated’ directionality); (d). Search function: search by either drug or protein. For
example, search all records for ESR1 protein.
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A case study on drug efficacy evaluation with C2Maps
Drug efficacy can be measured by the ability of a drug
to produce the desired phenotypic effect or molecular
effect. To evaluate drug efficacy in the molecular level
based on our hypothesis illustrated in Figure 2, we need
to know how drugs can affect the expression of its inter-
acting genes and how those genes are expressed in dis-
ease conditions. We have got the former from the above
case study of C2Maps. To get the latter, we performed
differential analysis on a well-studied microarray
Figure 6 Web Interface for CMap Annotation data curation. (a) Annotation Data: main search page allowing either public browse or
authorized curation; (b) Curator login: require login to curate directionality for certain disease; (c) User sign up: application form to create an
account as a curator; (d) Data Browse: the browse page after login; (e) Data Edit: update or delete previously curated records; (f) Data Entry: 1.
select disease; 2. relevant protein based on 1; 3. relevant drug based on 2; 4. relevant PubMed ID based on both 2 and 3; 5. relevant abstract
based on PubMed ID from 4; 6. Curate directionality based on 5.
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dataset-GSE3191[27]. This experiment contains breast
cancer subtype luminal A, basal-like and also normal
breast tissues. We obtained the differential genes for
both breast cancer subtypes - luminal A and basal-like
when compared to normal. We identified 579 differen-
tial genes between luminal A and normal, 773 differen-
tial genes between basal like and normal. We used these
two sets for the following case study.
Tamoxifen efficacy and toxicity assessment for the breast
cancer subtype - luminal A
Tamoxifen is a standard drug clinically used for breast
cancer and has 15 interacting proteins with directionality
annotations from C2Maps (shown in Table 5).We inter-
sected differential genes from luminal A microarray
experiment with Tamoxifen’s interacting partners from
C2Maps. Four proteins out of 15 are differentially
expressed between luminal A and normal, including
ESR1. In Figure 7c, drugs are represented as hexagons
and proteins as circles. The size of a protein node is pro-
portional to the rp score, an indication of importance of
this protein to breast cancer. Red nodes stand for over-
expressed proteins in breast cancer while green ones
represent under-expressed proteins. For edges between
drugs and proteins, red symbolizes that the drug activates
the protein while green symbolizes inhibition. From the
Figure, Tamoxifen has 3 therapeutic effects: it inhibits
over-expressed ESR1, activates under-expressed JUN and
activates MYC. Tamoxifen also has one toxic effect, acti-
vating over-expressed ERBB2, which might help explain
certain side effects when using Tamoxifen. Considering
that ESR1 is more significant for breast cancer compared
with the other three proteins, overall, Tamoxifen has
more of a therapeutic value in Luminal A patients by
reversing the gene expression of important disease pro-
teins in the network level (Figure 7c).
Tamoxifen efficacy and toxicity assessment for the breast
cancer subtype - basal-like
In Figure 7d, we portray the drug protein interaction for
Tamoxifen in basal patients. Three proteins out of its 15
interacting proteins are differentially expressed between
basal patients and normal. Tamoxifen has only 1
therapeutic effect by activating under-expressed JUN,
while 2 toxic effects by activating over-expressed E2F1
and inhibiting under-expressed IRS1. However, all these
three proteins are relatively insignificant for breast can-
cer. This implies a neutral role overall when using
Tamoxifen in basal patients since it is not able to
reverse its interacting proteins in basal condition (Figure
7d). This agrees well with the clinical fact that basal or
triple negative breast cancer patients fail to benefit from
Tamoxifen treatment.
Plicamycinefficacy and toxicity assessment for the breast
cancer subtype - luminal A
Plicamycin was an approved antineoplastic antibiotic for a
variety of advanced forms of cancer. It has been with-
drawn from market in 2000. In Figure 7f, we showed the
drug protein interaction for Plicamycin in Luminal A
patients. It has 2 interacting proteins with directionality
annotations (shown in Table 5) and both are not signifi-
cant in breast cancer with a low rp score. Only 1 protein
out of these 2 is differentially expressed between luminal
A and normal. Plicamycin has a toxic effect overall by
inhibiting under-expressed MYC. This implied a neutral
or toxic effect when using Plicamycin in Luminal A sub-
type breast cancer patientssince it is not able to reverse its
interacting proteins in the disease condition (Figure 7f).
This may help explain why it was withdrawn in 2000.
Conclusions
In this study, we present an upgraded C2Maps platform to
evaluate drug pharmacological effects based on the
hypothesis that an ideal drug can reverse the gene expres-
sion level in a disease back to those in normal conditions.
This online platform will enable users to query high-
coverage protein-drug connectivity maps in real time. It
enables users to research up-to-date knowledge of connec-
tivity maps for a specific disease, explore therapeutic pro-
tein targets, design repurposed drug compounds, and
assess toxicological impacts of drug compounds on dis-
ease-relevant genes/proteins. Three efficacy case studies
prove the feasibility to apply the literature mined drug
directionality data from C2Maps for drug efficacy study. It
will be a major resource to biomedical researchers
Table 4 Performance assessment of C2Maps in varying cancers.
Bladder Breast Leukemia Lung Lymphoma Melanoma Ovary Pancreas Prostate
Sensitivity 80.84% 79.80% 83.16% 78.44% 81.20% 77.39% 80.88% 84.99% 82.84%
Specificity 87.11% 84.91% 86.11% 89.37% 87.60% 91.53% 84.34% 86.45% 88.38%
ACC 86.70% 84.27% 85.63% 87.86% 86.78% 90.17% 84.09% 86.34% 87.93%
PPV 30.51% 43.01% 53.39% 54.06% 48.92% 49.24% 28.84% 33.82% 38.88%
F-Score 44.30% 55.89% 65.03% 64.01% 61.05% 60.19% 42.52% 48.38% 52.92%
The experiment were performed using a protein interaction confidence minimum threshold of 3 star and above (i.e., reliability score of >0.75) and retrieved drug
p-value at a minimum threshold of 0.05. The detailed evaluation procedures and measurement definitions, they can be found in the “Method FAQ” page of our
C2Maps website and as supplemental materials.
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interested in developing disease-specific therapeutic and
diagnostic applications based on progresses in network
biology and network pharmacology.
Discussion
From the case study on breast cancer drug effect evalua-
tion, we can see that there is still room for improvement,
although the two breast cancer drugs were well-evalu-
ated. The information for judging whether a drug has
global therapeutic effects on other diseases is limited due
to the manual curation procedure. This information is
very valuable for drug repurposing, however. In the cur-
rent version of C2Maps, drug-protein pairs are mainly
come from literature mining based on disease-gene
Figure 7 Breast cancer case study for drug pharmacological effect evaluation with C2Maps. (a) Distribution of directionality categories for
breast cancer; (b) A drug-target subnetwork with directionality information specific for Tamoxifen; (c) Drug effect evaluation for Tamoxifenon
breast cancer subtype - luminal A; (d) Drug effect evaluation for Tamoxifenon breast cancer subtype - basal-like; (e) A drug-target subnetworkwith
the directionality information specific for Plicamycin; (f) Drug effect evaluation for Plicamycinon breast cancer subtype - luminal A.
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searching and network mining, which can be supplemen-
ted by plenty of publicly-available drug target databases.
We will continue to update C2Maps and improve its
usability through achieving the following functionalities
in the near future.
1) We will increase the functionality of drug-orien-
tated searching for relevant disease phenotypes and
proteins in the C2Maps. It will allow users to input
drug names, not just disease names. It should be
able to retrieve all the disease names and genes/pro-
teins related to this drug. This function will be very
useful for drug repurposing.
2) We will increase the functionality of disease-
orientated browsing for relevant proteins and drugs
in the C2Maps by using disease phenotype trees. It
will allow users to browse the database by clicking
the disease name. The current version only supports
the disease-specific searching function without any
browsing function.
3) We will also enhance the functionality of interac-
tive directionality information annotation for drug-
protein pairs in the C2Maps by using natural lan-
guage processing (NLP) techniques. The literature
curations for breast cancer, colorectal cancer and
Alzheimer disease took three experts nearly one
year’s effort to complete. While this ensures the data
quality, it’s time consuming. With those golden stan-
dard dataset from curation, we will NLP techniques
to allow users to curate and annotate directionality
information from PubMed abstracts more easily and
semi-automatically.
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